To make a difference, the first step is to understand canine OA and how it can affect your patients’ lives.
Canine OA is characterized by intermittent inflammation and degradation of cartilage, leading to chronic, progressive pain and mobility challenges.
As a veterinarian, you want the best for your patients. You want them to live healthy and active lives, even when living with OA. Understanding the important risk factors and knowing how to intervene early is crucial to you providing the best possible care.
It’s a common misconception that dogs only develop osteoarthritis as a result of old age. In fact, there are many factors that place dogs at greater risk for canine OA, even in their early years.
Some breeds of dog are more susceptible to joint problems than others, and may be more genetically predisposed to conformational abnormalities such as hip and elbow dysplasia, and osteochondrosis.1
Rigorous or strenuous exercise can place greater stress on joints and make them more susceptible to injury, which initiates structural changes that progress the disease.1
Prior joint injuries or surgeries, such as cranial cruciate ligament injuries, are a common cause of OA in dogs.1
Excess weight places more stress on joints and puts them under greater pressure, leading to faster progression and severity of canine OA.1
Recognizing the causes of OA is important, but it doesn’t stop there. Find more useful resources below to get up to speed on canine OA.
COAST is an innovative canine OA staging tool designed by a consortium of international experts in veterinary surgery and pain management. With COAST, you can start the conversation about canine OA with pet owners before it sets in, and monitor OA over time.
Galliprant is a non-COX-inhibiting NSAID that delivers targeted, effective pain relief from the earliest diagnosed stages of OA.2* Start managing OA pain with Galliprant.
Canine OA is a progressive disease that can affect dogs during any stage of life.
*The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg)
Galliprant is an NSAID that controls pain and inflammation associated with osteoarthritis in dogs.
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.
Contact your Elanco or distributor representative, or call Elanco (1-888-545-5973) to discover how you can incorporate Galliprant into your canine OA protocol today.
© 2022 Elanco or its affiliates. Galliprant, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.